Inbec上市了吗？

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill compound preparation centered on the new generation integrase inhibitor dolutegravir (DTG) for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Triumeq is a once-daily three-in-one drug developed by ViiV Healthcare, a joint venture of GlaxoSmithKline and Pfizer. The drug is based on the treatment regimen of the integrase inhibitor Tivicay (Dolutegravir) and also contains two nucleoside reverse transcriptase inhibitors, Abacavir and Lamivudine. It was approved by the FDA on August 27, 2014.

Wu Hao, director of the Infection Center of You'an Hospital Affiliated to Capital Medical University, said in an interview with the E-drug manager that there are currently two mainstream directions in the global treatment of AIDS. One follows the European and American guidelines, and the other follows the World Health Organization guidelines (which are guidelines formulated by the WHO based on various factors such as the economy, resources, population income and other factors in underdeveloped areas). Currently, in the field of global AIDS treatment, DTG drugs are the only first-line drugs recommended by four guidelines (including IAS-USA, DHHS, EACS, and WHO). Since 1999, GSK has been approved for a total of eight HIV treatment drugs in China, and currently three products are on the national free catalog.

What is launched this time is China's first complete single-piece three-in-one preparation with DTG as the core, filling the gap in single-piece compound preparations. GSK has previously had a DTG drug on the market, with the trade name Tevicay. It was launched in the United States in 2013, but it needs to be used in combination with other drugs. Suimeikai is a complete single-tablet three-in-one preparation with DTG as the core. It can be taken once a day, one pill at a time, without considering factors such as food, environment, location, etc. AIDS is generally recognized as a chronic disease. "For chronic diseases, patient compliance is particularly important. Taking one pill once a day reduces the frequency and dosage of medication and significantly enhances patient compliance." Xu Ding added, "In the past, disease control focused more on the front end, but now more and more attention is paid to the back end. How patients use medications and their rational use also saves medical resources."